G U Corsini
Overview
Explore the profile of G U Corsini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Viaggi C, Vaglini F, Pardini C, Caramelli A, Corsini G
Neuropharmacology
. 2009 Mar;
56(8):1075-81.
PMID: 19298832
Evidence for involvement of cytochrome P450 2E1 in the MPTP-induced mouse model of PD has been reported [Vaglini, F., Pardini, C., Viaggi, C., Bartoli, C., Dinucci, D., Corsini, G.U., 2004....
2.
Tripathi P, Sgado P, Scali M, Viaggi C, Casarosa S, Simon H, et al.
Neuroscience
. 2009 Feb;
159(2):842-9.
PMID: 19186208
The En2 gene, coding for the homeobox-containing transcription factor Engrailed-2 (EN2), has been associated to autism spectrum disorder (ASD). Due to neuroanatomical and behavioral abnormalities, which partly resemble those observed...
3.
Viaggi C, Vaglini F, Pardini C, Sgado P, Caramelli A, Corsini G
J Neural Transm Suppl
. 2007 Nov;
(72):159-63.
PMID: 17982890
In order to reach a deeper insight into the mechanism of diethyldithiocarbamate (DDC)-induced enhancement of MPTP toxicity in mice, we showed that CYP450 (2E1) inhibitors, such as diallyl sulfide (DAS)...
4.
Ceravolo R, Sgado P, Frosini D, Corsini G
J Neural Transm Suppl
. 2007 Apr;
(71):133-41.
PMID: 17447424
An important goal in Parkinson's Disease research is to identify neuroprotective therapy, and the interaction between basic science and clinical research is needed to discover drugs that can slow or...
5.
Viaggi C, Pardini C, Vaglini F, Corsini G
J Neural Transm Suppl
. 2006 Oct;
(70):173-6.
PMID: 17017526
Elucidation of the biochemical steps leading to the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-induced degeneration of the nigro-striatal dopamine (DA) pathway has provided new clues to the pathophysiology of Parkinson's Disease (PD). In line...
6.
Maggio R, Armogida M, Scarselli M, Salvadori F, Longoni B, Pardini C, et al.
Neurotox Res
. 2003 Jul;
1(4):285-97.
PMID: 12835096
Epidemiological studies have shown a reduced incidence of cancer in Parkinson's disease. Since nearly all parkinsonian patients with clinical impairment are treated with L-beta-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine (DA)ergic agonists, a...
7.
Vaglini F, Pardini C, Viaggi C, Corsini G
Funct Neurol
. 2002 May;
16(4 Suppl):107-12.
PMID: 11996504
No abstract available.
8.
Chiarenza A, Scarselli M, Novi F, Lempereur L, Bernardini R, Corsini G, et al.
Eur J Pharmacol
. 2002 Jan;
433(1):47-54.
PMID: 11755133
We tested the ability of dopamine, apomorphine, phenylethylamine and pergolide to inhibit the proliferation of fetal calf serum-stimulated human breast cancer (MCF)-7 cells. While the first three compounds were able...
9.
Scarselli M, Armogida M, Pardini C, Chiacchio S, Corsini G
Adv Neurol
. 2001 Sep;
86:367-72.
PMID: 11553998
No abstract available.
10.
Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, et al.
J Biol Chem
. 2001 May;
276(32):30308-14.
PMID: 11373283
Evidence for heterodimerization has recently been provided for dopamine D(1) and adenosine A(1) receptors as well as for dopamine D(2) and somatostatin SSTR(5) receptors. In this paper, we have studied...